- This event has passed.
Sachs 21st Annual Biotech in Europe Forum (BEF)
October 7, 2021 @ 8:00 am - October 8, 2021 @ 5:00 pm
We are pleased to announce that the 21st Annual Biotech in Europe Forum (BEF) will take place on the 7th – 8th of October 2021 and will be a part of the digital Sachs Autumn Life Sciences Week, that also incorporates the 8th Annual HealthTech Investment Forum.
In view of the worldwide spread of the Delta variant and reluctance of our usual delegates to travel we have decided not to hold any part of the BEF programme as an in person event. Both HTIF and BEF will be delivered virtually, so allowing us to support our community and past attendees. We will provide both the usual stimulating programme, including live sessions, and the networking opportunities through the online meeting system.
Back for its 21st Annual Edition, this global bio-pharma industry event will address through its programme the main challenges for 2021 in investment, partnering and alliance management and prospects for 2022. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners.
The main programme for the 21st Annual BEF is spread throughout 2 days (7th-8th of October) and will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 15 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of Spotlight presentations, which will be delivered live as part of the main programme, other presentations will be added under company showcases and will be available on demand. We anticipate 650+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, bankers and advisors.
